Robust anti‐obesity and metabolic effects of a dual <scp>GLP</scp> ‐1/glucagon receptor peptide agonist in rodents and non‐human primates

Abstract

Repeated administration of MEDI0382 elicits profound weight loss in DIO mice and non-human primates, produces robust glucose control and reduces hepatic fat content and fasting insulin and glucose levels. The balance of activities at the GLP-1 and glucagon receptors is considered to be optimal for achieving weight and glucose control in overweight or obese Type 2 diabetic patients.